Bifogade filer
Kurs
+1,32%
Likviditet
74,3 MSEK
Kalender
Est. tid* | ||
2026-02-05 | 08:00 | Bokslutskommuniké 2025 |
2025-10-23 | 08:00 | Kvartalsrapport 2025-Q3 |
2025-07-16 | - | Kvartalsrapport 2025-Q2 |
2025-05-09 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
2025-05-08 | - | Årsstämma |
2025-04-29 | - | Kvartalsrapport 2025-Q1 |
2025-02-05 | - | Bokslutskommuniké 2024 |
2024-12-11 | - | Extra Bolagsstämma 2025 |
2024-10-24 | - | Kvartalsrapport 2024-Q3 |
2024-07-16 | - | Kvartalsrapport 2024-Q2 |
2024-05-15 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
2024-05-14 | - | Årsstämma |
2024-04-25 | - | Kvartalsrapport 2024-Q1 |
2024-02-08 | - | Bokslutskommuniké 2023 |
2023-10-30 | - | Kvartalsrapport 2023-Q3 |
2023-08-15 | - | Extra Bolagsstämma 2023 |
2023-07-18 | - | Kvartalsrapport 2023-Q2 |
2023-05-10 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
2023-05-09 | - | Årsstämma |
2023-04-27 | - | Kvartalsrapport 2023-Q1 |
2023-02-08 | - | Bokslutskommuniké 2022 |
2022-10-27 | - | Kvartalsrapport 2022-Q3 |
2022-07-19 | - | Kvartalsrapport 2022-Q2 |
2022-05-11 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
2022-05-10 | - | Årsstämma |
2022-04-28 | - | Kvartalsrapport 2022-Q1 |
2022-02-10 | - | Bokslutskommuniké 2021 |
2021-10-28 | - | Kvartalsrapport 2021-Q3 |
2021-07-21 | - | Kvartalsrapport 2021-Q2 |
2021-05-05 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
2021-05-04 | - | Årsstämma |
2021-05-04 | - | Kvartalsrapport 2021-Q1 |
2021-02-18 | - | Bokslutskommuniké 2020 |
2020-10-22 | - | Kvartalsrapport 2020-Q3 |
2020-07-16 | - | Kvartalsrapport 2020-Q2 |
2020-05-14 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
2020-05-13 | - | Årsstämma |
2020-04-29 | - | Kvartalsrapport 2020-Q1 |
2020-02-13 | - | Bokslutskommuniké 2019 |
2019-10-31 | - | Kvartalsrapport 2019-Q3 |
2019-07-17 | - | Kvartalsrapport 2019-Q2 |
2019-05-10 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
2019-05-09 | - | Årsstämma |
2019-04-25 | - | Kvartalsrapport 2019-Q1 |
2019-02-20 | - | Bokslutskommuniké 2018 |
2018-10-31 | - | Kvartalsrapport 2018-Q3 |
2018-07-18 | - | Kvartalsrapport 2018-Q2 |
2018-05-11 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
2018-05-09 | - | Årsstämma |
2018-04-26 | - | Kvartalsrapport 2018-Q1 |
2018-02-22 | - | Bokslutskommuniké 2017 |
2017-10-25 | - | Kvartalsrapport 2017-Q3 |
2017-07-19 | - | Kvartalsrapport 2017-Q2 |
2017-05-05 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
2017-05-04 | - | Årsstämma |
2017-04-28 | - | Kvartalsrapport 2017-Q1 |
2017-02-16 | - | Bokslutskommuniké 2016 |
2016-10-27 | - | Kvartalsrapport 2016-Q3 |
2016-07-15 | - | Kvartalsrapport 2016-Q2 |
2016-05-24 | - | Årsstämma |
2016-05-20 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
2016-04-27 | - | Kvartalsrapport 2016-Q1 |
2016-02-26 | - | Bokslutskommuniké 2015 |
2015-10-29 | - | Kvartalsrapport 2015-Q3 |
2015-07-17 | - | Kvartalsrapport 2015-Q2 |
2015-05-07 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
2015-05-06 | - | Årsstämma |
2015-05-06 | - | Kvartalsrapport 2015-Q1 |
2015-02-19 | - | Bokslutskommuniké 2014 |
2014-10-30 | - | Analytiker möte 2014 |
2014-10-30 | - | Kvartalsrapport 2014-Q3 |
2014-07-18 | - | Kvartalsrapport 2014-Q2 |
2014-05-09 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
2014-05-08 | - | Årsstämma |
2014-05-08 | - | Kvartalsrapport 2014-Q1 |
2014-02-20 | - | Bokslutskommuniké 2013 |
2013-11-05 | - | Kapitalmarknadsdag 2013 |
2013-11-05 | - | Analytiker möte 2013 |
2013-10-30 | - | Kvartalsrapport 2013-Q3 |
2013-07-18 | - | Kvartalsrapport 2013-Q2 |
2013-04-29 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
2013-04-26 | - | Årsstämma |
2013-04-26 | - | Kvartalsrapport 2013-Q1 |
2013-02-21 | - | Bokslutskommuniké 2012 |
2012-10-30 | - | Analytiker möte 2012 |
2012-10-30 | - | Kvartalsrapport 2012-Q3 |
2012-07-19 | - | Kvartalsrapport 2012-Q2 |
2012-04-27 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
2012-04-26 | - | Årsstämma |
2012-04-26 | - | Kvartalsrapport 2012-Q1 |
2012-02-23 | - | Bokslutskommuniké 2011 |
2011-11-29 | - | Kapitalmarknadsdag 2011 |
2011-10-20 | - | Kvartalsrapport 2011-Q3 |
2011-08-24 | - | Extra Bolagsstämma 2011 |
2011-07-19 | - | Kvartalsrapport 2011-Q2 |
2011-04-29 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
2011-04-28 | - | Årsstämma |
2011-04-20 | - | Kvartalsrapport 2011-Q1 |
2011-02-23 | - | Bokslutskommuniké 2010 |
2010-10-26 | - | Kvartalsrapport 2010-Q3 |
2010-07-20 | - | Kvartalsrapport 2010-Q2 |
2010-04-28 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
2010-04-27 | - | Kvartalsrapport 2010-Q1 |
2009-04-29 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
2008-04-25 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
2007-05-04 | - | X-dag ordinarie utdelning SOBI 0.00 SEK |
Beskrivning
Land | Sverige |
---|---|
Lista | Large Cap Stockholm |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
Sobi® will unveil new data at the annual European Association for Haemophilia and Allied Disorders (EAHAD 2025) congress in Milan from the 4th - 7th February, 2025. Outcomes and analyses investigating the effectiveness of ALTUVOCT® and Elocta® in adults, adolescents, and children with haemophilia A will be presented, further showcasing Sobi's commitment to advancing standards of care in haemophilia.
"People with haemophilia can experience bleeding episodes that can cause pain, irreversible joint damage, and life-threatening haemorrhages," said Lydia Abad-Franch, MD, MBA, Head of Research, Development, and Medical Affairs, and Chief Medical Officer at Sobi. "At EAHAD 2025, Sobi's poster and oral presentations will demonstrate the important progress that has been made in the treatment of haemophilia A, as we continue to move the treatment paradigm towards normal haemostasis. We look forward to sharing our findings in Milan."
Key data to be presented at EAHAD 2025 | ||
ALTUVOCT (efanesoctocog alfa) Joint with Sanofi. | Two-Year Clinical Outcomes of Once-Weekly Efanesoctocog Alfa Prophylaxis in Children with Severe Haemophilia A: Second Interim Analysis of the XTEND-ed Phase 3 Study | Oral presentation. #OR12 Session date: Friday, 07 February 2025 Presentation time: 13:45-15:15 |
ALTUVOCT (efanesoctocog alfa) Joint with Sanofi. | Efanesoctocog Alfa for the Perioperative Management of Patients with Severe Haemophilia A: 4 years of Experience in the XTEND Clinical Program | Oral presentation. #OR02 Session date: Friday, 07 February 2025 Presentation time: 08:30 - 10:00 |
ALTUVOCT (efanesoctocog alfa) Joint with Sanofi. | Clinical outcomes over 3 years of efanesoctocog alfa in adults and adolescents with severe haemophilia A: European results from the second interim analysis of XTEND-ed | Poster presentation. #PO109 Session date: Wednesday, February 5, 2025 Presentation time: 6:30 - 7:30 |
ALTUVOCT (efanesoctocog alfa) Joint with Sanofi. | Clinical outcomes over 2 years of efanesoctocog alfa in children with severe haemophilia A: European results from the second interim analysis of XTEND-ed | Poster presentation. # PO148 Session date: Wednesday, February 5, 2025 Presentation time: 6:30 - 7:30 |
ALTUVOCT (efanesoctocog alfa) Joint with Sanofi. | Treatment of Bleeding Episodes with Efanesoctocog Alfa in Adults and Adolescents with Severe Haemophilia A: Second Interim Analysis of the XTEND-ed Long-term Extension Study | Poster presentation. #PO060 Session date: Wednesday, February 5, 2025 Presentation time: 6:30 - 7:30 |
ALTUVOCT (efanesoctocog alfa) Joint with Sanofi. | Patient characteristics in FREEDOM, a study evaluating physical activity and joint health in patients with haemophilia A receiving efanesoctocog alfa prophylaxis | Poster presentation. #PO047 Session date: Wednesday, February 5, 2025 Presentation time: 6:30 - 7:30 |
ALTUVOCT (efanesoctocog alfa) | Assessment of treatment schedule, factor VIII trough level, and area under the curve for efanesoctocog alfa vs an extended half-life FVIII comparator: a modelling approach | Poster presentation. #PO115 Session date: Wednesday, February 5, 2025 Presentation time: 6:30 - 7:30 |
ALTUVOCT (efanesoctocog alfa) | Impact of a hypothetical switch to efanesoctocog alfa prophylaxis on bleeding, treatment burden and area under the curve in severe haemophilia A: Italian CHESS III cohort analysis | Poster presentation. #PO127 Session date: Welcome Reception, Wednesday, February 5, 2025 Presentation time: 6:30 - 7:30 |
Elocta®/Eloctate® (efmoroctocog alfa) | Real-World Effectiveness and Usage of a Recombinant Factor VIII Fc: Interim Analysis in Adults from the 48-Month Prospective, Observational A-MORE Study | Poster presentation. #PO120 Session date: Wednesday, February 5, 2025 Presentation time: 6:30 - 7:30 |
Elocta®/Eloctate® (efmoroctocog alfa) | Real-World Effectiveness and Usage of a Recombinant Factor VIII Fc: Interim Analysis in Children and Adolescents from the 48-Month Prospective, Observational A-MORE Study | Poster presentation. #PO079 Session date: Wednesday, February 5, 2025 Presentation time: 6:30 - 7:30 |
About ALTUVOCT®
ALTUVOCT (efanesoctocog alfa) [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein] (formerly BIVV001) is the first high-sustained FVIII replacement therapy with the potential to deliver near-normal factor activity levels for a significant part of the week, improving bleed protection in a once-weekly dose for people with haemophilia A. Efanesoctocog alfa builds on the established Fc fusion technology by innovatively adding a region of von Willebrand factor and XTEN® polypeptides to extend its time in circulation. It is the only therapy that has been shown to break through the von Willebrand factor ceiling, which imposes a half-life limitation on current factor VIII therapies. The European Commission granted Orphan Drug designation in June 2019 It is approved and marketed as ALTUVOCT™ by Sobi in Europe. It is approved and marketed as ALTUVIIIO™ [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl] by Sanofi in the United States, Japan, and Taiwan.
About Elocta®/Eloctate®
Elocta®/Eloctate® (efmoroctocog alfa) is a recombinant clotting factor therapy developed for haemophilia A using Fc fusion technology to prolong circulation in the body. It is engineered by fusing factor VIII to the Fc portion of immunoglobulin G subclass 1, or IgG1 (a protein commonly found in the body), enabling Elocta to use a naturally occurring pathway to extend the time the therapy remains in the body (half-life). Elocta is manufactured using a human cell line in an environment free of animal and human additives. Elocta is approved and marketed by Sobi for the treatment of haemophilia A in the EU, the UK, Iceland, Kuwait, Liechtenstein, Norway, Saudi Arabia and Switzerland. It is approved and marketed as Eloctate® (Antihemophilic Factor [Recombinant], Fc Fusion Protein) by Sanofi in the United States, Canada Japan, Australia, New Zealand and other countries, where Sanofi has the marketing rights.
About Sobi®
Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology, and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia, and Australia. In 2023, revenue amounted to SEK 22.1 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.
Contacts
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.